Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Ordenar por: 

RelevânciaAutorTítuloAnoImprime registros no formato resumido
Registros recuperados: 2
Primeira ... 1 ... Última
Imagem não selecionada

Imprime registro no formato completo
Expression of the antibody 14D9 in Nicotiana tabacum hairy roots Electron. J. Biotechnol.
Martínez,Carolina; Petruccelli,Silvana; Giulietti,Ana María; Alvarez,María Alejandra.
Nicotiana tabacum hairy roots that express the antibody 14D9 were established. The 14D9 antibody yield obtained after 20 days of culture was 5.95 μg 14D9ml-1. The addition of the reticulum endoplasmic retention sequence KDEL demonstrated a positive effect over the intracellular 14D9 amounts with a yield increase up to 20.82 µg ml-1. DMSO increased the antibody amount in the biomass from 20.00 to 64.03 µg ml-1 while PVP (at 1.5 gl-1) and gelatine (at 5.0 gl-1) increased total 14D9 amounts in the culture medium to 25 µg and 14 µg respectively
Tipo: Journal article Palavras-chave: Catalytic antibodies; In vitro cultures; Molecular farming; Recombinant antibodies; Tobacco.
Ano: 2005 URL: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-34582005000200006
Imagem não selecionada

Imprime registro no formato completo
Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals BJPS
Pucca,Manuela Berto; Bertolini,Thaís Barboza; Barbosa,José Elpidio; Galina,Simone Vasconcelos Ribeiro; Porto,Geciane Silveira.
Monoclonal antibodies represent the fastest growing class of biopharmaceutical products and have a host of applications in medical research, diagnosis, therapy, and basic science. The production of recombinant monoclonal antibodies has revolutionized the generation of immunoglobulins, and their use represents a strategic breakthrough, affecting the global pharmaceutical market for therapeutic proteins. In the present work, a review of scFv, and the number of related patents, has been carried out. The results show that several countries have scFv patents, most notably the United States, China and United Kingdom. The target of these scFv antibodies was also assessed and the results demonstrate that most are directed toward cancer therapy.
Tipo: Info:eu-repo/semantics/article Palavras-chave: Monoclonal antibodies; Recombinant antibodies; ScFv; Biopharmaceuticals.
Ano: 2011 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502011000100005
Registros recuperados: 2
Primeira ... 1 ... Última
 

Empresa Brasileira de Pesquisa Agropecuária - Embrapa
Todos os direitos reservados, conforme Lei n° 9.610
Política de Privacidade
Área restrita

Embrapa
Parque Estação Biológica - PqEB s/n°
Brasília, DF - Brasil - CEP 70770-901
Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco

Valid HTML 4.01 Transitional